Cohance Lifesciences Executive and Leadership Team

Yann D'Herve, the Chief Executive Officer at Cohance Lifesciences, directs the overarching corporate strategy for the global CDMO operations. D'Herve architects the long-term vision for small molecule and ADC development, ensuring alignment with the evolving needs of pharmaceutical innovators. By fostering partnerships across international markets, the Chief Executive Officer drives the expansion of clinical analytical services. Yann D'Herve maintains constant oversight of the company's commercial scale capabilities, ensuring that discovery-to-commercialization pipelines remain efficient and robust. This leadership role involves coordinating with the Board to prioritize investments in high-growth therapeutic areas. Through the implementation of advanced manufacturing protocols, the Chief Executive Officer secures the competitive position of the organization within the global pharmaceutical landscape. D'Herve consistently monitors market trends to adapt the service portfolio, ultimately ensuring that the company remains a premier partner for complex molecule development and manufacturing requirements.

Umang Vohra, the Executive Chairman & Global Chief Executive Officer at Cohance Lifesciences, governs the strategic direction and governance framework of the entire organization. Vohra oversees the integration of global business units, ensuring that the CDMO services align with international quality benchmarks. By managing high-level stakeholder relationships, the Executive Chairman & Global Chief Executive Officer drives the company's mission to support pharmaceutical innovators from discovery through commercial scale. Umang Vohra architects the organizational structure to facilitate seamless collaboration across diverse therapeutic segments, including nucleic acid chemistry and ADCs. This leadership role involves setting the tone for corporate sustainability initiatives and operational excellence. Through the guidance of the Executive Chairman & Global Chief Executive Officer, the company maintains a strong market presence. Vohra ensures that the firm consistently delivers value to clients by optimizing the development pipeline and enhancing the overall efficiency of complex molecule manufacturing processes.

Somesh Sharma, the Chief Operating Officer at Cohance Lifesciences, manages the daily execution of API development and manufacturing workflows. Sharma directs the operational teams to ensure that clinical analytical services meet stringent regulatory requirements. By streamlining internal processes, the Chief Operating Officer drives improvements in production cycle times for pharmaceutical partners. Somesh Sharma coordinates with other C-suite leaders to align manufacturing capacity with client demand across global markets. This leadership role involves the oversight of facility performance and the implementation of quality control measures that define the company's reputation for excellence. Through the management of cross-functional teams, the Chief Operating Officer ensures that complex molecule projects transition smoothly from initial discovery to full-scale commercial production. Sharma maintains a focus on operational scalability, ensuring that the infrastructure supports the growing needs of the pharmaceutical industry while upholding the highest standards of safety and precision in every manufacturing batch.

Ravinath Shetty, the Chief Operating Officer, Platform at Cohance Lifesciences, architects the specialized technical platforms required for Antibody Drug Conjugates and nucleic acid chemistry. Shetty directs the development of proprietary methodologies that enable the company to handle highly complex molecular structures. By overseeing the platform-specific infrastructure, the Chief Operating Officer, Platform drives innovation in the CDMO service offerings. Ravinath Shetty ensures that the technical capabilities remain at the forefront of the industry, allowing the firm to tackle unique challenges in drug development. This leadership role involves close collaboration with research teams to translate scientific breakthroughs into scalable manufacturing processes. Through the optimization of these specialized platforms, the Chief Operating Officer, Platform supports the company's goal of accelerating the pipeline for pharmaceutical innovators. Shetty monitors the performance of these technical assets to ensure consistent delivery of high-quality results, thereby reinforcing the organization's status as a trusted partner for advanced pharmaceutical manufacturing.

Sunil Uttarwar, the Chief Operating Officer, Technology Operations at Cohance Lifesciences, manages the integration of advanced manufacturing technologies across all production sites. Uttarwar directs the deployment of automated systems and digital tools that enhance the precision of API manufacturing. By overseeing the technological backbone of the company, the Chief Operating Officer, Technology Operations drives efficiency and sustainability in the production environment. Sunil Uttarwar ensures that all technology-driven processes comply with global regulatory standards, facilitating the seamless delivery of services to pharmaceutical clients. This leadership role involves the continuous assessment of manufacturing equipment and the implementation of upgrades to support complex molecule production. Through the strategic application of technology, the Chief Operating Officer, Technology Operations supports the company's commitment to quality and innovation. Uttarwar maintains a focus on operational reliability, ensuring that the technological infrastructure remains robust enough to handle the diverse and demanding requirements of the global pharmaceutical market.

Gaurav Bahadur, the Chief Human Resources Officer at Cohance Lifesciences, directs the talent acquisition and organizational development strategies that support the company's global workforce. Bahadur architects programs designed to foster a culture of innovation, quality, and sustainability among the staff. By overseeing human capital management, the Chief Human Resources Officer drives the recruitment of top-tier scientific and operational talent necessary for CDMO success. Gaurav Bahadur coordinates with the executive team to ensure that the organizational structure supports the company's strategic goals in the pharmaceutical sector. This leadership role involves the implementation of training initiatives that keep the workforce aligned with the latest industry standards and technical requirements. Through the development of robust performance management systems, the Chief Human Resources Officer ensures that the organization maintains a high level of operational excellence. Bahadur focuses on employee engagement and retention, which are critical for sustaining the company's long-term growth and its reputation as a premier partner for pharmaceutical innovators.